Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint
Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint of the composite outcome of cardiovascular mortality and recurrent CV clinical events up